Looks like you’re on the UK site. Choose another location to see content specific to your location

Alleged Collusion in Generic Drug Pricing Exposed in Major Lawsuit Filed by Aetna
A major lawsuit from Aetna, part of CVS Health, accuses nearly two dozen pharmaceutical companies, including Teva and Pfizer, of colluding to limit competition in the generic drug market. This alleged conspiracy has led to substantial price hikes for generic medications, impacting consumers and challenging the competitive landscape within the healthcare industry.
The lawsuit, initiated by Aetna, alleges that the accused pharmaceutical companies engaged in a “fair share” scheme, orchestrating market divisions and controlling market shares for specific generic drugs. By doing so, these companies reportedly avoided competitive pricing strategies, which traditionally drive down costs for consumers opting for generics over brand-name drugs.
The complaint describes a coordinated effort, executed through private meetings and communications, that enabled the companies to artificially maintain or increase prices, undermining fair competition. Among those named in the lawsuit are prominent players such as Actavis Pharma, Mylan Pharmaceuticals, and Novartis. While most companies have yet to respond publicly, the allegations highlight significant ethical and legal questions about the conduct of major pharmaceutical firms within the industry.
Aetna’s lawsuit shines a light on suspected unethical practices within the generic drug industry, emphasising the broader implications for industry competition and medication affordability. As the legal proceedings unfold, the case may prompt increased scrutiny of pharmaceutical practices and regulatory oversight, potentially leading to substantial shifts in market dynamics and consumer trust in the healthcare sector.
Contact Marcus for more details.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard